Multiple Chinese developers of antibody-drug conjugates (ADCs) are now turning their focus to bispecific candidates based on different target combinations as they look to diversify their expertise in the fast-growing field.
The fresh drive for bispecifics has quickened pace over the past few months on the back of a huge licensing deal worth up to $8.4bn for the EGFR x HER3-targeting ADC BL-B01D1, struck last December between Bristol Myers Squibb Company and Systimmune Inc., a US-based subsidiary of China's Sichuan Biokin Pharmaceutical
Key Takeaways
-
Chinese biotechs' fresh drive to develop bispecific ADCs has quickened on the back of an up to $8.4bn licensing deal with BMS for the EGFR x HER3-targeting ADC BL-B01D1.
-
Developers in the country are exploring broader combinations of targets for bispecifics
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?